JP2021531754A5 - - Google Patents
Info
- Publication number
- JP2021531754A5 JP2021531754A5 JP2021500735A JP2021500735A JP2021531754A5 JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5 JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002212A JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695623P | 2018-07-09 | 2018-07-09 | |
| US201862695627P | 2018-07-09 | 2018-07-09 | |
| US62/695,623 | 2018-07-09 | ||
| US62/695,627 | 2018-07-09 | ||
| US201962863710P | 2019-06-19 | 2019-06-19 | |
| US62/863,710 | 2019-06-19 | ||
| US201962864367P | 2019-06-20 | 2019-06-20 | |
| US62/864,367 | 2019-06-20 | ||
| US201962866420P | 2019-06-25 | 2019-06-25 | |
| US62/866,420 | 2019-06-25 | ||
| PCT/US2019/041085 WO2020014285A2 (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Division JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531754A JP2021531754A (ja) | 2021-11-25 |
| JP2021531754A5 true JP2021531754A5 (enExample) | 2022-07-08 |
| JP7617839B2 JP7617839B2 (ja) | 2025-01-20 |
Family
ID=69141640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Active JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535669B2 (enExample) |
| EP (1) | EP3820496A4 (enExample) |
| JP (2) | JP7617839B2 (enExample) |
| KR (1) | KR20210042909A (enExample) |
| CN (2) | CN112672753B (enExample) |
| AU (1) | AU2019301070B2 (enExample) |
| CA (1) | CA3105750A1 (enExample) |
| IL (1) | IL279965A (enExample) |
| SG (1) | SG11202100208VA (enExample) |
| WO (1) | WO2020014285A2 (enExample) |
| ZA (3) | ZA202100390B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102742741B1 (ko) * | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| CN113573782B (zh) * | 2018-12-21 | 2025-12-16 | Ose免疫疗法公司 | 针对人pd-1的双功能分子 |
| CN110734498A (zh) * | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| JP7495489B2 (ja) * | 2019-10-21 | 2024-06-04 | ナンチン リーズ バイオラブス カンパニー，リミティド | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 |
| US20230044248A1 (en) | 2019-11-01 | 2023-02-09 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| US20230340122A1 (en) | 2019-11-05 | 2023-10-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| EP4097220A4 (en) * | 2020-01-30 | 2024-03-20 | ImmunityBio, Inc. | ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| KR20230003178A (ko) * | 2020-04-29 | 2023-01-05 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | PD-1 및 TGF-β에 대한 이중 기능성 단백질 |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| CA3183673A1 (en) * | 2020-06-26 | 2021-12-30 | Robert Allen | Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2022063314A1 (zh) * | 2020-09-28 | 2022-03-31 | 上海君实生物医药科技股份有限公司 | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| EP4251650A4 (en) * | 2020-11-27 | 2024-10-23 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
| WO2022172085A2 (en) * | 2021-02-15 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| WO2022174451A1 (zh) * | 2021-02-22 | 2022-08-25 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| CN112979802B (zh) * | 2021-04-21 | 2021-08-03 | 上海普铭生物科技有限公司 | 抗人il-33单克隆抗体及其应用 |
| CN113249330A (zh) * | 2021-05-20 | 2021-08-13 | 深圳市先康达生命科学有限公司 | 免疫细胞及其应用 |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| US20250134998A1 (en) * | 2021-08-30 | 2025-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
| EP4396341A4 (en) * | 2021-08-31 | 2025-07-09 | Texas A & M Univ Sys | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM |
| US20240391990A1 (en) * | 2021-09-03 | 2024-11-28 | Nan TANG | Bi-functional fusion protein and uses thereof |
| EP4430194A4 (en) * | 2021-11-12 | 2025-08-20 | Georgia Tech Res Inst | ADENOSINE DEAMINASE 2 COMPOSITIONS AND METHODS OF USE THEREOF |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| AU2022435471A1 (en) * | 2022-01-18 | 2024-05-30 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| CN114540311A (zh) * | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其应用 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| WO1998035039A1 (en) | 1997-02-06 | 1998-08-13 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
| CN1257545A (zh) | 1997-04-18 | 2000-06-21 | 拜奥根有限公司 | Ⅱ型TGF－β受体/免疫球蛋白恒定区融合蛋白 |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2334322A2 (en) | 2008-08-21 | 2011-06-22 | Asterion Limited | Glp-1 fusion polypeptides |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2014309199B2 (en) * | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| US20170158749A1 (en) * | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| WO2016191283A2 (en) | 2015-05-22 | 2016-12-01 | University Of Houston System | Enzymatic immunomodulation of solid tumors and user thereof |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| EP3487998B1 (en) | 2016-07-19 | 2023-07-12 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| JP7573365B2 (ja) | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
| US10906957B2 (en) | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| CN110198738A (zh) | 2017-01-07 | 2019-09-03 | 默克专利有限公司 | 用于靶向的TGF-β抑制的给药方案和剂型 |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| AU2018266103B2 (en) | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| CN110050000B (zh) | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| BR112020022145A2 (pt) * | 2018-05-04 | 2021-01-26 | Merck Patent Gmbh | inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| SG11202105975SA (en) * | 2018-12-06 | 2021-07-29 | Guangdong Tcrcure Biopharma Technology Co Ltd | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| JP2022537068A (ja) * | 2019-06-23 | 2022-08-23 | グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド | 抗ａｌｐｐ ｃａｒ－ｔ細胞療法 |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
-
2019
- 2019-07-09 CN CN201980058963.8A patent/CN112672753B/zh active Active
- 2019-07-09 KR KR1020217003783A patent/KR20210042909A/ko not_active Ceased
- 2019-07-09 AU AU2019301070A patent/AU2019301070B2/en active Active
- 2019-07-09 CA CA3105750A patent/CA3105750A1/en active Pending
- 2019-07-09 WO PCT/US2019/041085 patent/WO2020014285A2/en not_active Ceased
- 2019-07-09 EP EP19834221.4A patent/EP3820496A4/en active Pending
- 2019-07-09 US US16/506,981 patent/US11535669B2/en active Active
- 2019-07-09 CN CN202510846429.0A patent/CN120775065A/zh active Pending
- 2019-07-09 SG SG11202100208VA patent/SG11202100208VA/en unknown
- 2019-07-09 JP JP2021500735A patent/JP7617839B2/ja active Active
-
2021
- 2021-01-05 IL IL279965A patent/IL279965A/en unknown
- 2021-01-19 ZA ZA2021/00390A patent/ZA202100390B/en unknown
-
2022
- 2022-11-23 US US18/058,364 patent/US12703747B2/en active Active
-
2023
- 2023-01-10 ZA ZA2023/00423A patent/ZA202300423B/en unknown
-
2025
- 2025-01-07 JP JP2025002212A patent/JP2025063123A/ja active Pending
- 2025-01-09 ZA ZA2025/00319A patent/ZA202500319B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7450684B2 (ja) | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 | |
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| JP2025063123A5 (enExample) | ||
| US20180127502A1 (en) | Novel pd-1 immune modulating agents | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| WO2006020258A2 (en) | Novel tetravalent bispecific antibody | |
| CN101432015A (zh) | 功能性抗体 | |
| JP2021512151A5 (enExample) | ||
| JP2024518200A (ja) | Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物 | |
| Müller et al. | Bispecific Antibodies | |
| CA3082036C (en) | MONOSPACTIC AND BISPACTIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION ROLE FOR CANCER TREATMENT | |
| JP2022512891A5 (enExample) | ||
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| CA3147420A1 (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| JP2024539630A5 (enExample) | ||
| TW202542198A (zh) | Cd137結合分子及其用途 | |
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| WO2023178253A2 (en) | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| Compte et al. | Applications of trimerbodies in cancer immunotherapy | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| CA3205494A1 (en) | Bispecific antibody for specifically neutralizing tgf-.beta. signal of helper t cell, and pharmaceutical combination and use thereof | |
| US12606617B2 (en) | Composition comprising an IgE antibody |